Takeda to Use Zinfandel TOMM40 Biomarker Assay for Alzheimer's Drug Study | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Takeda Pharmaceutical Company will use a biomarker assay developed by Zinfandel Pharmaceuticals as part of a clinical trial investigating the utility of Takeda's drug Actos in Alzheimer's disease, the companies said this week.

Under the terms of the agreement, Takeda has taken an exclusive, worldwide license for the use of Zinfandel's TOMM40 assay as a biomarker for the risk of Alzheimer's disease in high-risk older adults with normal cognition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.